JAK
Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.
- Cat.No. 产品名称 Information
-
GC25992
TG-89
TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
-
GC25869
RO495
RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
-
GC25168
Brepocitinib (PF-06700841)
Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
-
GC67867
VVD-118313
-
GC66329
NDI-034858
-
GC65453
JAK-IN-3
-
GC65405
JAK2-IN-6
-
GC65387
Tyk2-IN-5
-
GC64959
JAK/HDAC-IN-1
-
GC64701
Povorcitinib
-
GC64700
Povorcitinib phosphate
-
GC64372
Lorpucitinib
-
GC64108
Ifidancitinib
-
GC63864
(E/Z)-Zotiraciclib hydrochloride
-
GC63448
JAK-IN-14
-
GC63416
Itacnosertib
-
GC63309
Ilunocitinib
-
GC63029
JAK1-IN-8
-
GC62908
Coumermycin A1
-
GC62665
JAK2/FLT3-IN-1 TFA
-
GC62500
JAK2-IN-7
-
GC62491
BMS-986202
-
GC62313
Izencitinib
-
GC62246
G5-7
G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2.
-
GC62233
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
A TYK2 inhibitor
-
GC62130
(2R,5S)-Ritlecitinib
-
GC62112
Zotiraciclib
Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.
-
GC61807
(E/Z)-AG490
-
GC50480
PF 06651600 malonate
Potent and selective JAK3 inhibitor
-
GC50066
Atiprimod dihydrochloride
JAK2 inhibitor
-
GC39081
Reticuline
-
GC37971
ZM39923
A potent inhibitor of JAK3
-
GC37847
Tyk2-IN-8
Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
-
GC37846
Tyk2-IN-7
-
GC37575
Ruxolitinib sulfate
A potent, selective JAK1/JAK2 inhibitor
-
GC37523
RGB-286638 free base
A multi-kinase inhibitor
-
GC37522
RGB-286638
A multi-kinase inhibitor
-
GC36882
PF-06263276
-
GC36783
NVP-BSK805 dihydrochloride
A potent, selective JAK2 inhibitor
-
GC36646
Momelotinib Mesylate
-
GC36366
JAK-IN-10
-
GC36365
JAK3 covalent inhibitor-1
-
GC36364
JAK2-IN-4
-
GC36363
JAK1-IN-7
-
GC36351
Itacitinib adipate
A JAK1 inhibitor
-
GC35554
Brevilin A
A sesquiterpene lactone with anticancer activity
-
GC34973
(3S,4S)-Tofacitinib
-
GC34972
(3S,4R)-Tofacitinib
-
GC34971
(3R,4S)-Tofacitinib
-
GC43406
Delphinidin (chloride)
Natural vasorelaxant and inhibitor of EGFRs and HATs